scholarly journals P2Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

2019 ◽  
Vol 2019 (4) ◽  
Author(s):  
Maria-Pia Abbracchio ◽  
Jean-Marie Boeynaems ◽  
José L. Boyer ◽  
Geoffrey Burnstock ◽  
Stefania Ceruti ◽  
...  

P2Y receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on P2Y Receptors [3, 5]) are activated by the endogenous ligands ATP, ADP, uridine triphosphate, uridine diphosphate and UDP-glucose. The relationship of many of the cloned receptors to endogenously expressed receptors is not yet established and so it might be appropriate to use wording such as 'uridine triphosphate-preferring (or ATP-, etc.) P2Y receptor' or 'P2Y1-like', etc., until further, as yet undefined, corroborative criteria can be applied [46, 109, 187, 375, 388].Clinically used drugs acting on these receptors include the dinucleoside polyphosphate diquafosol, agonist of the P2Y2 receptor subtype, approved in Japan for the management of dry eye disease [236], and the P2Y12 receptor antagonists prasugrel, ticagrelor and cangrelor, all approved as antiplatelet drugs [52, 316].

2021 ◽  
Vol 2021 (3) ◽  
Author(s):  
Maria-Pia Abbracchio ◽  
Jean-Marie Boeynaems ◽  
José L. Boyer ◽  
Geoffrey Burnstock ◽  
Stefania Ceruti ◽  
...  

P2Y receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on P2Y Receptors [3, 5, 192]) are activated by the endogenous ligands ATP, ADP, uridine triphosphate, uridine diphosphate and UDP-glucose. The relationship of many of the cloned receptors to endogenously expressed receptors is not yet established and so it might be appropriate to use wording such as 'uridine triphosphate-preferring (or ATP-, etc.) P2Y receptor' or 'P2Y1-like', etc., until further, as yet undefined, corroborative criteria can be applied [47, 110, 190, 383, 396]. Clinically used drugs acting on these receptors include the dinucleoside polyphosphate diquafosol, agonist of the P2Y2 receptor subtype, approved in Japan for the management of dry eye disease [241], and the P2Y12 receptor antagonists prasugrel, ticagrelor and cangrelor, all approved as antiplatelet drugs [53, 323].


2018 ◽  
Vol 7 (6) ◽  
pp. 35 ◽  
Author(s):  
Momoko Kitazawa ◽  
Chiaki Sakamoto ◽  
Michitaka Yoshimura ◽  
Motoko Kawashima ◽  
Sachiko Inoue ◽  
...  

2014 ◽  
pp. 327 ◽  
Author(s):  
Simon Skalicky ◽  
Oliver Lau ◽  
Chameen Samarawickrama

1978 ◽  
Vol 174 (2) ◽  
pp. 671-672 ◽  
Author(s):  
G J Wishart

After the administration of 3-methylcholanthrene to adult male rats, activities of hepatic UDP-glucuronosyltransferase towards six from a group of 12 substrates were stimulated by 250-350%. Activities towards the remaining six substrates were unaffected. Conversely, after phenobarbital administration, activities formerly stimulated by 3-methylcholanthrene remained unchanged, and the other six activities were stimulated by 160-280%. The relationship of these two groups of transferase activities to other evidence suggesting the same heterogeneity of the enzyme is discussed.


2021 ◽  
Vol 22 (11) ◽  
pp. 6133
Author(s):  
Aytan Musayeva ◽  
Subao Jiang ◽  
Yue Ruan ◽  
Jenia Kouchek Zadeh ◽  
Panagiotis Chronopoulos ◽  
...  

The parasympathetic nervous system is critically involved in the regulation of tear secretion by activating muscarinic acetylcholine receptors. Hence, various animal models targeting parasympathetic signaling have been developed to induce dry eye disease (DED). However, the muscarinic receptor subtype (M1–M5) mediating tear secretion remains to be determined. This study was conducted to test the hypothesis that the M3 receptor subtype regulates tear secretion and to evaluate the ocular surface phenotype of mice with targeted disruption of the M3 receptor (M3R−/−). The experimental techniques included quantification of tear production, fluorescein staining of the ocular surface, environmental scanning electron microscopy, assessment of proliferating cells in the corneal epithelium and of goblet cells in the conjunctiva, quantification of mRNA for inflammatory cytokines and prooxidant redox enzymes and quantification of reactive oxygen species. Tear volume was reduced in M3R−/− mice compared to age-matched controls at the age of 3 months and 15 months, respectively. This was associated with mild corneal epitheliopathy in the 15-month-old but not in the 3-month-old M3R−/− mice. M3R−/− mice at the age of 15 months also displayed changes in corneal epithelial cell texture, reduced conjunctival goblet cell density, oxidative stress and elevated mRNA expression levels for inflammatory cytokines and prooxidant redox enzymes. The findings suggest that the M3 receptor plays a pivotal role in tear production and its absence leads to ocular surface changes typical for DED at advanced age.


2021 ◽  
Vol Volume 15 ◽  
pp. 3811-3820
Author(s):  
Zaina Al-Mohtaseb ◽  
Scott Schachter ◽  
Bridgitte Shen Lee ◽  
Jaclyn Garlich ◽  
William Trattler

Sign in / Sign up

Export Citation Format

Share Document